Milk thistle to treat non-alcoholic fatty liver disease: Dream or reality'

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 8, 2013, Pages 677-679

  Abenavoli, Ludovico ^a   Bellentani, Stefano ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b AUSL Modena   (Italy)

Author keywords

hepatoprotective; insulin resistance; milk thistle; non alcoholic fatty liver disease; silymarin

Indexed keywords

ALPHA TOCOPHEROL; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; METFORMIN; PIOGLITAZONE; SILIBININ; SILYBUM MARIANUM EXTRACT; SILYMARIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOPHILICITY; LIVER PROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PLANT SEED; PROTEIN EXPRESSION; REVIEW; TRADITIONAL MEDICINE; TREATMENT DURATION; TREATMENT PLANNING;

ANIMALS; FATTY LIVER; HUMANS; LIVER; MILK THISTLE; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; SILYMARIN; TREATMENT OUTCOME;

EID: 84887388357     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.842893     Document Type: Review

References (20)

1. Bellentani S, Scaglioni F, Marino M et al. Epidemiology of non-Alcoholic fatty liver disease. Dig. Dis. 28(1), 155-161 (2010).
2. Nascimbeni F, Pais R, Bellentani S et al. From nafld in clinical practice to answers from guidelines. J. Hepatol. 59(4), 859-871 (2013).
3. Day CP, James OF. Steatohepatitis: A tale of two "hits"' Gastroenterology 114(4), 842-845 (1998).
4. Petta S, Muratore C, Craxì A. Non-Alcoholic fatty liver disease pathogenesis: The present and the future. Dig. Liver Dis. 41(9), 615-625 (2009).
5. Abenavoli L, Milic N. Dietary intervention in non-Alcoholic fatty liver disease. J. Acad. Nutr. Diet. 113(2), 211 (2013).
6. Loria P, Adinolfi LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian association for the study of the liver (AISF) expert committee. Dig. Liver Dis. 42(4), 272-282 (2010).
7. Abenavoli L, Capasso R, Milic N et al. Milk thistle in liver diseases: Past, present, future. Phytother. Res. 24(10), 1423-1432 (2010).
8. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 61(14), 2035-2063 (2001).
9. Gazak R, Walterova D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr. Med. Chem. 14(3), 315-338 (2007).
10. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev. 17(4), CD003620 (2007).
11. Salamone F, Galvano F, Cappello F et al. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl. Res. 159(6), 477-486 (2012).
12. Basiglio CL, Sánchez Pozzi EJ et al. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem. Biol. Interact. 179(2-3), 297-303 (2009).
13. Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World J. Gastroenterol. 17(18), 2288-2301 (2011).
14. Velussi M, Cernigoi AM, De Monte A et al. Long term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need, and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 26(4), 871-879 (1997).
15. Hajaghamohammadi AA, Ziaee A, Raflei R. The efficacy of silymarin in decreasing transaminase activities in nonalcoholic fatty liver disease. A randomized controlled clinical trial. Hepat. Mon. 8, 191-195 (2008).
16. Hasjiani E, Hasahemi SJ. Comparison of therapeutic effects of Silymarin and Vitamin E in nonalcoholic fatty liver disease: Results of an open-label, prospective, randomized study. JJNPP 4, 8-14 (2009).
17. Loguercio C, Federico A, Trappoliere M et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: A pilot study. Dig. Dis. Sci. 52(9), 2387-2395 (2007).
18. Loguercio C, Andreone P, Brisc C et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med. 52(9), 1658-1665 (2012).
19. Serviddio G, Bellanti F, Giudetti AM et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther. 332(3), 922-932 (2010).
20. Saller R, Brignoli R, Melzer J et al. An updated systematic review with meta-Analysis for the clinical evidence of silymarin. Forsch. Komplementmed. 15(1), 9-20 (2008).